There is a lot of evidence on the disparities in cancer care, but less on how to take those findings and turn them into actionable items to address the problem, said Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance.
There is a lot of evidence on the disparities in cancer care, but less on how to take those findings and turn them into actionable items to address the problem, said Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance.
Transcript
There is more research on disparities in health, and cancer specifically, but is the data and research actionable for providers, health systems, and policy makers?
So, there is a growing body of literature that actually speaks to what we're calling implementation science. How do you do things in a different way that actually can impact the health and the well-being of communities?
My colleagues and I were very honored to publish an article earlier in January of this year that provided an actionable framework for how to reduce cancer disparities. And it was a broad sweeping article that looked at the different components of cancer care. One of the things that we did was we talked to experts around the country about what they were doing. What are some of the things that they were doing that are actionable that we perhaps could share with the rest of the nation?
And so, we know that the cancer care continuum has several leaky areas where people fall through—whether it be from screening, prevention, treatment—and so we pulled that together in that article that really helps to outline an actionable framework.
Beyond that, there are some folks who are doing work that is, again, really driven towards what are the things that we can do versus just doing the descriptive work, which we know—we've been describing the problems in terms of cancer disparities for decades. It's time to do something. We do need more.
But there are some data that's out there around some actionable items. We just need to do more of that work.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More